Treatment Program for Anemia in AIDS Patients

Completed · Not applicable

Conditions studied: HIV Infections, Cytopenias

In brief

The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.

Key facts

Study ID

NCT00002022

Run by

R W Johnson Pharmaceutical Research Institute

Last updated by the study team

2005-06-24

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Co-existing Condition:
• Patients with the following are excluded:
• Life expectancy < 3 months.
• = or < grade 4 performance score.
• AIDS-related dementia.
• Uncontrolled hypertension.
• Acute symptomatic opportunistic infection or other AIDS-defining illness.
• Patients with the following are excluded:
• Life expectancy < 3 months.
• = or < grade 4 performance score.
• AIDS-related dementia.
• Uncontrolled hypertension.
• Acute symptomatic opportunistic infection or other AIDS-defining illness.
• Patients must have:
• A clinical diagnosis of AIDS.
• Hematocrit < 30 percent.
• Endogenous serum erythropoietin level = or < 500 U/ml.
• A life expectancy = or > 3 months.
• > Grade 4 performance score.

Where it is running

• R W Johnson Pharmaceutical Research Institute — Raritan, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.